Using a panel of cDNA microarrays comprising 47 650 transcript elements, we have carried out a dual-channel analysis of gene expression in 39 resected primary human non-small cell lung tumours versus normal lung tissue. Whilst *11 000 elements were scored as differentially expressed at least twofold in at least one sample, 96 transcripts were scored as over-represented fourfold or more in at least seven out of 39 tumours and 30 sequences 16-fold in at least two out of 39 tumours, including 24 transcripts in common. Transcripts (178) were found under-represented fourfold in at least seven out of 39 tumours, 31 of which are underrepresented 16-fold in at least two out of 39 lesions. The relative expression levels of representative genes from these lists were analysed by comparative multiplex RT -PCR and found to be broadly consistent with the microarray data. Two dramatically over-represented genes, previously designated as potential tumour suppressors in breast (maspin) and lung and breast (S100A2) cancers, were analysed more extensively and demonstrate the effectiveness of this approach in identifying potential lung cancer diagnostic or therapeutic targets. Whilst it has been reported that S100A2 is downregulated in NSCLC at an early stage, our microarray, cmRT -PCR, Western and immunohistochemistry data indicate that it is strongly expressed in the majority of tumours.
Introduction
The lack of generally effective therapies for lung cancer leads to the high mortality rate associated with this common disease. Recorded 5-year survival figures vary, to some extent perhaps reflecting differences in ascertainment methods, but across Europe are approximately 10% (Bray et al., 2002) . Whilst surgery is an effective strategy for the treatment of localized lesions, most patients present with overtly or covertly disseminated disease. Unfortunately, despite the many advances in chemotherapeutic regimes, for most lung cancer patients, metastatic disease present at diagnosis will be fatal. We have chosen to use microarray transcript profiling to illuminate potential targets with application in the detection or treatment of this disease.
Microarray analysis allows a reversal of the standard cancer genetics paradigm. Instead of attempting to identify areas of the genome which are perturbed in disease and then looking for key cancer-associated genes within these regions, the technology allows us to first identify genes that are differentially expressed in a condition and then to look at the genomic context of that abnormal expression. Perhaps the most powerful prioritization tool in the search for disease significance will be the coupling of gene expression changes to genomic damage events in the tumour DNA.
Lung cancer is commonly divided into small cell (SCLC) and non-small cell (NSCLC) disease. SCLC, approximately 20% of cases, is invariably metastatic at presentation and is therefore treated primarily through the use of chemotherapeutic agents. In contrast, NSCLC may appear to be localised or only locally metastatic and therefore amenable to surgical resection. NSCLC is further subdivided into three main classes, squamous cell carcinoma, adenocarcinoma and large cell carcinoma. However, many if not most tumours are composed of multiple histological types (Thurlbeck and Churg, 1995; Fraire et al., 1987) . Such variation in a presumably clonal lesion has led to the suggestion that lung cancers arise from a multipotential stem cell component of the normal tissue, a hypothesis supported by the analysis of model systems (Sunday et al., 1999) . It is very likely that transcript profiling will lead to further subdivisions within these overall classes of disease, some which mirror preexisting pathological classes and some which are novel (Garber et al., 2001; Bhattacharjee et al., 2001) . Whilst such classification regimes may be very important in understanding disease biology and may become critical in the future with respect to assessing lung cancer prognosis and directing subsequent therapeutic practice, such uses are perhaps currently secondary to the need for improved diagnostic and therapeutic agents.
Given that it is generally easier pharmacologically to inhibit rather than to replace function and given that a lung cancer diagnostic is likely to be most effective where it measures an excess of rather than the lack of a gene product, our attention has been directed primarily towards genes that are over-represented in disease tissue. However, it is likely that the study of underrepresented sequences will considerably enhance our understanding of the biology of the disease process and may lead to the discovery of linked and more conventional targets. We have therefore generated and validated gene lists of both tumour over and under-represented sequences.
Results

Method validation
Dual channel microarray hybridizations were carried out in duplicate for six patients comprising tumour against matched normal tissue across five cDNA microarrays: Human Drug Target (formerly known as Human Genome GEM TM 1) and Human Foundation 1 -4 (formerly known as Human Genome GEM 2 -5) (Incyte Genomics, Inc.). Clones representing 14 distinct genes (http://www.roycastle.org/research/) with a differential expression (DE) value greater than two in at least five of the six patients were selected. The validity of these predictions was tested by an independent gene expression analysis, comparative multiplex RT -PCR (cmRT -PCR). As many of the standard control genes are known to be variable in expression between different human tissues and states (Lee et al., 2002) we selected new control genes from within the array data; sequences that showed DE values below two in the tumour versus normal hybridizations from the first six patients. Control primer sets were validated against each other in reactions with paired cDNA samples. The most robust of the tested control loci in terms of ease of amplification and wide reaction compatibility was the KIAA0228 (228) gene (Acc: D86981), located on 17q23.2. We used cmRT -PCR and at least one control gene to test the 14 genes identified as differentially expressed (83 individual hybridised elements). The cmRT -PCR data was consistent with the hybridization data predicting a gene expression difference between the tumour and normal tissue, in each case, in the same direction.
As additional verification, we independently assayed expression profiles of two of these genes, osteopontin and PRAME, using multiplex quantitative real-time RT -PCR (TaqMan TM , Applied Biosystems) with the housekeeping gene b2-microglobulin as an internal reference (Figure 1 ). Osteopontin was found to be over-represented at least fourfold in 14 out of 14 tumours assayed, with an average C T (cycle threshold of detectable logarithmic phase amplification) of 22 in lung tumours and 32 in normal tissue. PRAME was measured as over-represented in 13 out of 14 tumours, with an average C T of 28 in tumours and 36 in normal tissue. Our microarray approach for identifying overrepresented genes in lung tumours was thus confirmed by two distinct methods using independent control genes. Having validated the basic experimental protocol, a wider analysis was undertaken.
Microarray data analysis
RNA was extracted from resectable NSCLC tumours from 33 additional patients giving 39 in total, including 13 who had undergone neo-adjuvant chemotherapy (Table 1) . A further series of dual channel microarray Figure 1 Illustrates TaqMan TM quantitative real-time PCR data for matched normal lung and tumour pairs for osteopontin (a) and PRAME (c), confirming the over-representation of these genes in a majority of non-small cell lung tumours. The housekeeping gene b2-microglobulin was used as an internal reference for normalization of sample concentrations. Relative expression values (y-axis) were determined using normal lung tissue from patient 185 (detectably expressing both genes) as the calibrator. (b and d) show cmRT -PCR (b) and RT -PCR (d) analyses of osteopontin and PRAME in matched samples hybridizations was carried out for all patients comparing tumour against matched normal tissue (27 patients) or tumour against a pooled normal sample (six patients). For the majority of patient samples, duplicate hybridizations were performed across all five cDNA microarrays. The data presented in this study was obtained from 298 individual array analyses that passed hybridization QC, screening 34 -37 different patient samples across each of 47 650 clones representing 39 176 unique gene/EST clusters.
Approximately 11 000 clones were scored as significantly differentially expressed (4twofold: Yue et al., 2001) in at least one sample. We were primarily interested in identifying sequences dramatically differentially expressed in a wide range of disease samples, or else sequences that were very dramatically differentially expressed in a smaller number of tumours. Gene lists were constructed of (a) genes that were differentially expressed fourfold or more in seven or more (approximately 20%) tumours and (b) genes that were differentially expressed 16-fold or more in two or more tumours (Tables 2 and 3 ). Approximately 50% of the elements highlighted in the fourfold tumour overrepresented list were various immunoglobulin transcripts, the relative expression levels of which correlated with each other closely across the tumour series (data not shown). Removing these sequences left a list of 96 genes with Genbank annotation, some of which were represented in the primary list by multiple array elements. These remaining 96 were ranked in order of number of tumours in which the element passed the restriction criteria. Following removal of Igrelated genes, 30 elements were scored as overrepresented 16-fold or more in at least two tumours and of those, 24 were common to both lists. One hundred and seventy-eight non-Ig genes with Genbank annotation were scored as under-represented fourfold or more in seven or more tumours with 30 of these under-represented 16-fold in two or more lesions. One element, representing the calcium binding protein S100A8 (MRP8), was present in both the over and under-represented lists. The expression profile of this gene did not correlate closely with those of immunoglobulin related elements. M  67  2  0  X  IB  61  Large cell endocrine  M  73  2  1  X  IIB  64  Pulmonary carcinoid  M  79  1  0  X  IA  65  Adenocarcinoma  F  70  1  0  X  IA  67  Squamous  F  68  2  0  X  IB  69  Squamous  M  73  1  1  X  IIA  70  Adenocarcinoma  M  75  2  0  X  IB  74  Adenocarcinoma  F  71  1  0  X  IA  78  Squamous  M  66  2  0  X  IB  80  Squamous  M  70  3  1  X  IIB  83  Squamous  M  73  2  1  X  IIB Listed is the closest Genbank match to the Incyte cDNA element sequence, the most likely genomic position of the sequence (BLAT similarity), the number of times the element score exceeded the filter threshold, the number of times it was scored as differentially expressed (DE42) and the abbreviated Genbank annotation for the matched sequence 
Validation of expression measurements in gene lists
To confirm that the large-scale analysis had correctly identified significant and widely differentially expressed sequences, six genes across the range from the fourfold upregulated list and two from the fourfold down regulated list were selected. The DE value for the control gene KIAA0228 did not exceed two for any tumour/normal pair analysed. A second control locus with a DE 52 in all samples was selected (phosphatidylinositol transfer protein, PI-TPbeta, Genbank Accession D30037) and was validated across tumours and normal pairs against KIAA0228, within and outside the microarray analysed series. The expression alterations predicted were validated across a panel of paired cDNA samples generated from the RNA used in the microarray hybridizations (Figure 2a,b) . In each case, the RT -PCR data confirmed the direction of DE predicted by the microarray analysis. Of the tumour under-represented sequences tested; WIF1, a secreted inhibitor of the Wnt signalling pathway (Hsieh et al., 1999) , appeared to be markedly reduced in all but one tumour (T86: in which the gene appeared to be overrepresented in both array and cmRT -PCR analyses). Interestingly, g-catenin, a putative target of Wnt signalling (Kolligs et al., 2000) , was also variably over-represented in the tumour series (DE 42 in 14 out of 37 samples). Caveolin 1, a gene implicated as a tumour suppressor in some tissues, was also consistently and dramatically under-represented in the lung tumours. One hundred and six NSCLC tumours were subsequently screened by RFLP -PCR analysis for mutations within caveolin 1: codon 132, a region mutated in a sub-group of breast cancer patients (Hayashi et al., 2001) . No mutations were identified suggesting that alterations to this codon are unlikely to be important in lung cancer.
Maspin is mapped to a region of 18q21.33 approximately 150 Kb distal to the translocation targeted BCL2 gene and approximately 150Kb proximal to a second over-represented gene in the validated set, SCCA1 (duplicated in the genome). Whilst the array analysis suggested that BCL2 was marginally differentially expressed in only one tumour, a third gene in this region, SERPINB13, located between maspin and SCCA1, was found to be over-represented in some tumours. This observation was subsequently validated by cmRT -PCR (Figure 2b ) with SERPINB13 transcripts detected in a range of tumours but only very rarely, if at all, in normal lung tissue. Of the three serpin genes in this region, maspin, transcribed in the same direction as SERPINB13 and SCCA2 (SERPINB3) and in the opposite direction to BCLSCCA12, was the most frequently and specifically over-represented in the tumour tissues analysed. A similar result was obtained with respect to expression of these genes in lung cancer cell lines, with maspin being the most frequently expressed locus and only one line, LUDLU1, expressing all three serpins.
Western and immunohistochemical analysis of S100A2 levels
Our study indicated that the calcium-binding protein S100A2 was over-represented in the majority of nonsmall cell lung tumours, in contrast to the results shown by Feng et al. (2001) , which suggested that S100A2 expression is diminished in lung cancer cells from an early stage. To further analyse S100A2 expression and attempt to resolve this difference, we extended our investigations of this gene to the protein level. Western analysis of matched protein extracts from several tumour : normal tissue pairs with an S100A2 specific antibody was entirely consistent with the transcript data for those lesions in indicating a dramatic over-representation of the products of this gene in the tumour samples (Figure 3 ). These data were confirmed by an immunohistochemical analysis of a range of tumours, where intense staining, either cytoplasmic or both cytoplasmic and nuclear, was observed in tumour cells from a range of patients. In the samples examined, connective tissue was invariably negative for S100A2 antibody staining. Interestingly, in the normal lung from cancer patients, whilst the majority of cells were negative, strong nuclear staining of a layer of bronchial basal epithelial cells was observed (Figure 4 ).
Gene amplification analysis
For a number of validated loci, tumours were screened for evidence of gene amplification (or in the case of WIF1, homozygous loss) by cmPCR. Whilst in most cases we found no evidence for relative copy number changes in the disease tissue (maspin, MMP1, S100P, WIF1), clear data consistent with low-level amplification was obtained for the S100A2 gene from one out of 35 primary tumours, which as determined by cmRT -PCR analysis of adjacent tissue sections, appeared to strongly express the gene ( Figure 5 ). In the majority of cases tested, it seems likely that the gene expression changes observed are not driven by dramatic numerical alterations in tumour gene copy number.
Discussion
It has been suggested that there are two inter-related applications facilitated by microarray-based gene expression profiling: the identification of novel disease relevant targets and pathways, and tumour classification and stratification (Bertucci et al., 2001) . There are many recent examples of the use of disease profiles to stratify tumours into clinically relevant sub-groups. However, currently, there is little evidence that such a strategy would lead directly to an improvement in mortality rates for lung cancer patients, given that effective curative treatment options are very limited. Consequently, our primary aim was to design an analysis that might highlight potential new lung cancer targets. The relative expression of each gene element was where possible scored by reference to the patient matched normal lung tissue. Given that matched tissues have been through identical clinical procedures, such a strategy minimises apparent variation due to unequal degradation of mRNA. Additionally, it minimises any contribution from expression polymorphisms as it compares tissues with matched genotypes. No attempt was made to microdissect a pure tumour or normal epithelial component for these analyses. Given that the cell of origin of lung tumours is currently unclear, the use of microdissection to generate a normal-cell probe could in the worst case generate an irrelevant population. Considering the tumour tissue, whilst it is perhaps likely that tumourcell-overexpressed sequences will be the most effective targets, we are acutely aware of the counter-argument that gene products which are abnormally regulated in supporting non-malignant cells might be more easily exploited given that the non-neoplastic genomes of such cells are less fluid (Folkman et al., 2000) . The ideal lung cancer target would be highly specific for tumour tissue cells and should therefore be readily detected as an over-represented sequence by the analysis undertaken.
Of the genes identified in our over-represented lists, matrix metalloproteinase 1 (MMP1) stands out as being significantly associated with lung cancer. Whilst therapies directed against MMPs have not yet been shown to be clinically effective in the disease (Bonomi, 2002) , a promoter polymorphism, which it is argued influences basal expression levels of the gene, appears to modify lung cancer risk (Zhu et al., 2001) . Furthermore, Joos et al. (2002) concluded that polymorphisms in the MMP1 and MMP12 genes are either causative factors in smoking-related lung injury or are in linkage disequilibrium with causative polymorphisms. In comparing our data to other epithelial cancer profiles, it also is interesting to note that putative therapeutic targets in our lists have been identified a number of times in other malignancies. Specifically, osteopontin has been shown to be overrepresented in ovarian and colon cancer (Kim et al., 2002; Agrawal et al., 2002) and PRAME overrepresented in ovarian cancer (Welsh et al., 2001) . Similarly, S100A2 has been reported to be overexpressed in ovarian cancer (Hough et al., 2001) . However the gene lists are substantially different to those generated in other NSCLC studies (Garber et al., 2001; Bhattacharjee et al., 2001; Giordano et al., 2001; Nacht et al., 2001) . This is likely due to the different criteria used to build the lists in response to different primary aims (classification versus target identification). S100A2 has been implicated in lung cancer in a previous microarray analysis of a human cell line model system. Interestingly, it was concluded that this sequence was frequently down-regulated early in lung cancer development (Feng et al., 2001) . Indeed, on the basis of their data, the authors concluded that lack of S100A2 expression might be a useful marker of early disease and that therapeutic strategies designed to upregulate the expression of this gene might be appropriate. Supporting this argument is a number of expression studies that have implicated S100A2 as a breast tumour suppressor gene (Liu et al., 2000; Wicki et al., 1997) . However, our analysis on the expression of this gene in lung cancer differs from the earlier report by demonstrating a consistent and strong over-representation of this gene in multiple lung tumour samples. We observed comparatively high levels of mRNA and strong tumour cell-localized cytoplasmic and nuclear S100A2 protein expression raising the possibility that the product(s) of this gene may serve as a lung cancer diagnostic marker. Whilst the majority of normal cells appeared not to express S100A2, strong nuclear staining was observed in a layer of basal lung epithelial cells underlying the columnar epithelium of major airways. The basal cells are multipotent cells capable of differentiating into many of the mature epithelial cell types found in normal lung, raising the possibility that these particular cells may represent the precursors of the S100A2-expressing lung tumour cells. The difference in results observed in each study may be due to the different control material used, or due to differences between the cell model system and the primary tissues analysed and highlights the need to supplement and context tissue-derived transcript abundance data with in situ hybridization or immunohistochemical analyses of primary material.
A second gene, previously implicated as a tumour suppressor, the serine protease inhibitor maspin (SERPIN B5) was strongly over-represented in the majority of the tumours analysed. Maspin is thought to be down-regulated in breast and prostate cancer and functional analysis has suggested that the protein may act as a suppressor of metastasis (Seftor et al., 1998) . Paradoxically, Maass et al. (2001) reported that the sequence was strongly expressed relative to normal tissue in the majority of primary pancreatic tumours analysed and Umekita et al. (2002) in a recent study of breast cancer, suggested that strong expression of maspin is correlated with poor prognosis. The seemingly contradictory results of both S100A2 and maspin suggest that these and other genes perhaps not only behave differently in particular tumours, but also that they may play different roles in different tissue types and perhaps even within different components of a tissue.
In addition to MMP1, the generated gene list also contains a pre-existing anti-cancer drug target, DNA topoisomerase a (Topcu, 2001; Matsumoto et al., 2001) . Also represented are a number of putative Figure 4 Shows immunohistochemistry results for normal and tumour tissue. The primary antibody was the S100A2 specific polyclonal. Clear immunoreactivity is seen in the tumour, with stromal cells being negative. In some cases this strong staining appears to be cytoplasmic (69), in others cytoplasmic and nuclear. CmRT -PCR and Western data suggested that both 191T and 69T expressed high levels of S100A2 mRNA, observation consistent with these IHC data. In normal lung, expression (strong nuclear) appeared to be limited to a layer of basal epithelial cells immediately beneath the columnar epithelia lining the major airways Figure 3 Shows the Western analysis for S100A2 expression. Five tumours which strongly expressed S100A2 (Figure 2a and samples outside the array series) were selected on the basis of cmRT -PCR data. Approximately equivalent quantities of extracted proteins from matched normal and tumour samples were loaded. No immunoreactive protein was detected in tumour samples which were scored as negative for over-representation of S100A2 (not shown). Under the conditions used, the S100A2 specific antibody detected a small immunoreactive protein in the tumour samples only. The apparent size of this protein was smaller than predicted for S100A2 from sequence data (*11 kDa). PAGE-related discrepancies in apparent versus predicted size have previously been reported for S100 proteins (including S100A2) with mass spectrometry ultimately used to confirm the true molecular weights (Ilg et al., 1996) . However, we cannot rule out the possibility that the apparent molecular weight of the immunoreactive protein in tumours is related to alternative processing of either the S100A2 transcript or protein a b Figure 5 (a and b) Show cmPCR analyses of genomic DNA from tumour and normal samples. Tumour 78 shows a bias in both sets of reactions towards amplification of the S100A2 genomic versus control genomic products ((a) g-globin : chr 11 and (b) SPLIT-2: chr 4) compared to both the matched normal from patient 78 and further to a range of other normal and tumour samples. Control primers used were (a) g-globin and (b) SPLIT-2 sequences are putative therapeutic targets that would fall into the class of potentially drugable proteins. The requirements of a lung cancer detection or diagnostic reagent are less stringent being simply that the tumourencoded protein is ideally not represented in the specific diagnostic compartment (sputum, serum) unless a disease is present or imminent. The number of potential diagnostic targets in the list is therefore wider. In both cases, further pre-clinical validation studies are warranted.
Materials and methods
Clinical samples
Approval for this study was obtained from local ethics committees in Liverpool and Bern. Two sets of samples were used in the microarray analysis ( Table 2 ). The first (26) represented sequentially obtained resectable-staged NSCLCs and matched normal tissue from clinical centres in Liverpool, UK. The second series of paired tissues (13) were collected as part of a clinical trial of neo-adjuvant chemotherapy centred in Bern, Switzerland. These NSCLC patients were all staged IIIA on entry into the study and followed a course of three cycles of docetaxel and cisplatin therapy (days 1, 22 and 33) prior to resection (day 64) under SAKK protocol 16/96. Immediately following surgery, tumour tissue and matched normal lung tissue, approximately 10 cm distant from the primary lesion, were crudely dissected and snap frozen in liquid nitrogen. Both diseased and normal tissues were therefore matched with respect to the clinical procedure and collection process. The tumours used in this section of the analysis, with the exception of B2, all showed a clinical response to the neo-adjuvant therapy. Additional matched NSCLC tumour pairs from the Roy Castle tissue bank were used for extended cmRT -PCR, Taqman and mutation analysis.
Clinical sample processing
Three batches of 20, 40 mM frozen sections were cut from the tumour and normal samples (*1 cm diameter) and used respectively to extract RNA, protein and DNA. 5 mM sections flanking those used for RNA extraction and adjacent to those fronting the DNA and protein series were stained to show tumour histology and to estimate the overall percentage of viable overt tumour cells in the region analysed (which varied between 0% in one neo-adjuvant patient to 100%: mean value 60%). Total RNA was extracted from the tissues using a standard Trizol (Life Technologies) protocol (Heighway et al., 2003) . Following ethanol precipitation, the RNA was resuspended in 100 ml of RNase-free water and stored at -708C. Yields averaged 125 mg of total RNA from the tumours and 36 mg for the normal tissues. DNA was extracted by a standard SDS lysis/phenol extraction procedure (Heighway et al., 2003) .
Microarray analysis
mRNA was isolated from the total RNA samples with one round of poly(A) + selection as described in Yue et al. (2001) . Matched normal lung mRNA was not available from tumours 57, 65, 111, 132 and B9 and B14. The hybridizations for these samples were therefore run against a pooled normal sample drawn from the analysis series. To enable sufficient sample for the multiple hybridizations involved, mRNA isolated from each sample was subjected to T7 amplification as described in Pabon et al. (2001) . Reverse transcription and labelling reactions and hybridizations were performed as described in Yue et al. (2001) . Hybridizations were performed in duplicate across each array design. Axon GenePix TM scanners (Foster City, CA, USA) were used to scan the microarrays in both the Cy3 (535 nm) and Cy5 (625 nm) channels. The signals were subsequently converted to a resolution of 16 bits per pixel and balanced using the total Cy3 and Cy5 signals. The surrounding background was subtracted from each element signal, and Cy3 : Cy5 ratios were computed as described in Yue et al. (2001) .
Data analysis
The Incyte microarray platform has been extensively quality controlled . On the basis of these established performance criteria, a differential expression (DE) between the tumour and normal channel was considered significant if it exceeded twofold. The hybridization signal from each element was assessed with respect to (a) height of that signal above background and (b) signal diameter. A DE was only calculated if, in at least one channel, the signal to background ratio exceeded 2.5, the signal intensity was above 250 units, and the element diameter exceeded 40% of the mean element diameter for that array. In addition, control elements including spiked-in yeast DNA fragments and housekeeping genes were assessed as an additional measure of hybridization quality.
Before calculation of the DE a correction factor was applied to each Cy5 probe (corresponding to the tumour sample) element value to normalise system signal differences between the Cy3 and Cy5 channels arising from slight differences in RT or dye labelling efficiency. The Cy5 signal value was multiplied by a balance coefficient calculated as a ratio of the total Cy3 and total Cy5 signals. The DE values were exported from GEMTools TM software (Incyte Genomics, Inc., Palo Alto, CA, USA) into Microsoft Excel to allow averaging over duplicate hybridizations (most samples) as the median of the log(2) DE values for each element. The averaged data was subsequently imported into GeneSpring (Silicon Genetics) for all further data analysis.
RT -PCR
Tumour and normal tissue cDNA was synthesized from 1 ml aliquots of total RNA (*100 ng) in a 20 ml poly T-primed reaction using a Promega Reverse Transcription System (as directed) and was stored at -208C. cDNA was similarly prepared from cell line derived mRNA. 0.5 ml of this target cDNA was used in RT -PCR assays. A stock reaction mix was prepared which included (number of tubes+1) (42 ml dH 2 O, 5 ml of 106 Taq reaction buffer, 0.5 ml of each primer (0.25 mg), 0.5 ml of a 250 mM dNTP mix and 1.25 units of Roche Taq polymerase). The stock mix was vortexed after Taq addition and 49 ml added to each tube. The reactions were immediately cycled on Perkin Elmer 9600 machines at 948C for 2 min, 30 times (588C for 1 min, 748C for 1 min, 948C for 1 min) 588C for 2 min and 748C for 10 min. PCR products were visualized by UV illumination of 2.5% TBE agarose gels containing 0.5 mg/ml ethidium bromide
Primers
Primer sequences are available on request (or see http:// www.roycastle.org/research/). For RT -PCR, the primers were positioned such that the product obtained was cDNA Lung cancer target identification J Heighway et al specific. This was verified experimentally by test amplifications of cDNA and genomic DNA targets.
Comparative multiplex RT -PCR and PCR
Competitive reactions were carried out using four instead of two primers per reaction to concurrently amplify a test and a control locus. The reaction is therefore competitive, the ratio of final products being related to the initial transcript ratios. Following cDNA test amplifications containing 0.5 mg of each primer, and assuming that a test-gene product was actually obtained from the normal tissues, reactions were balanced such that the product intensity of the two genes under analysis was approximately equal in the normal sample. The balancing was carried out by sequentially reducing the concentration of the primers for the stronger gene product in the initial reaction, so reducing the efficiency of that amplification. The estimates of relative product intensity in the disease tissue were subsequently carried out visually where, patient-by-patient, the ratio of test to control locus in the normal tissue derived cDNA was compared to that in the tumour tissue amplification. To minimise experimental variation it is important that the normal and tumour cDNA from each patient are assayed in the same way, at the same time, using the same PCR reaction master mix and under identical conditions. Comparative multiplex PCR was carried out in an analogous way, using control primer sets from regions of the genome that are relatively unperturbed in lung cancer with respect to gene amplification and homozygous deletion.
TaqMan TM analysis
For quantitative real-time PCR analysis, cDNA was synthesized from 1 mg total RNA in a 25 ml reaction with 100 units M-MLV reverse transcriptase (Ambion), 0.5 mM dNTPs (Epicentre), and 40 ng/ml 71 random hexamers (Fisher). Reactions were incubated at 258C for 10 min, 428C for 50 min, and 708C for 15 min, diluted to 500 ml, and stored at -308C. PCR primers and probes, details on request, were designed using ABI Primer Express 1.5 software and synthesized by Applied Biosystems, Inc.
The QPCR reactions were performed using an ABI Prism 7700 Sequence Detection System in 25 ml total volume with 5 ml cDNA template, 16 TaqMan Universal PCR Master Mix (ABI), 100 nM each PCR primer, 200 nM probe, and 16 VIC-labelled Beta-2-Microglobulin endogenous control (ABI). Reactions were incubated at 508C for 2 min, 958C for 10 min, followed by 40 cycles of incubation at 958C for 15 s and 608C for 1 min. Results were analysed using Sequence Detector 1.7 software (ABI) and fold differences were calculated using the comparative C T method (ABI User Bulletin #2).
Western analysis
A standard Western protocol was used to examine protein levels of S100A2. 20, 40 mM sections were lysed by the addition of 1 ml of PE buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% w/v SDS, 0.5% v/v NP40 containing one protease inhibitor cocktail tablet (Roche) per 50 ml). Lysis was encouraged by vigorous pipetting and/or syringing of the mix. An equal volume of 26 tracking dye (100 mM Tris-HCl pH 6.8, 16% v/v glycerol, 3% w/v SDS, 8% v/v bmercaptoethanol, 0.04% w/v bromophenol blue) was added to the extract, which was subsequently boiled for 10 min. Approximately equal amounts of protein derived from matched normal and tumour sample were electrophoresed on standard 15% polyacrylamide gels and electroblotted overnight onto Immobilon-P membrane (Millipore). Following blocking for 4 h with 4% w/v milk powder in PBS containing 0.05% v/v Tween 20, the filter was immersed for 1 h in a 1/500 dilution of primary S100A2-specific rabbit polyclonal antibody (Dako). Following 365 min washes in PBS containing 0.05% v/v Tween 20, specifically bound primary was detected using a swine anti-rabbit secondary antibody, 45 min, 1/1000 dilution (Dako). Following 465 min washes, bound secondary was detected using an ECL+Plus enhanced chemiluminesence system (Amersham).
Immunohistochemical analysis of S100A2 expression
Five mM formalin-fixed, paraffin-embedded sections were dewaxed in xylene for 30 min followed by rehydration through a series of graded ethanols to water. Antigens were retrieved using a 15 min microwave treatment in Vector unmasking solution (10 mM sodium citrate buffer pH 6). Slides were washed in standing and running water for 15 and 5 min respectively prior to loading onto a Dako Autostainer. Endogenous peroxidase was blocked by 15 min incubation in 3% v/v H 2 O 2 and sections were incubated for 60 min in a 1/250 -1/500 dilution of S100A2 rabbit polyclonal antibody (Dako) followed by detection of specific staining with the Dako LSAB2 HRP system with diaminobenzidine substrate. The slides were counter stained in Haematoxilin/Scotts tap water and then dehydrated through a series of graded alcohols to xylene. Sections were mounted in DPX and visualized. In the negative control sections, the primary antibody was replaced by diluent.
